Type 2 diabetes and weight

Insulin moves glucose from the blood into cells. In type 2 diabetes the cells respond poorly to it, so the pancreas produces more, and eventually cannot produce enough to compensate.

Fat stored in the liver and around the abdominal organs is the part most implicated. It is metabolically active in a way that subcutaneous fat is not, releasing fatty acids and inflammatory signals that interfere with insulin action directly.

This is why waist measurement predicts diabetes risk better than BMI alone, and why two people at the same weight can have very different risk depending on where that weight sits.

Remission means blood glucose returning to a non-diabetic range and staying there without glucose-lowering medication. It is not the same as a cure, the underlying susceptibility remains, and weight regain generally brings the condition back.

The likelihood is strongly related to how much weight is lost and how long the person has had diabetes. Remission is most achievable in the earlier years after diagnosis, while the pancreas retains more of its insulin-producing capacity.

Any decision about reducing or stopping diabetes medication belongs with the clinical team managing it, and requires monitoring. Weight loss can reduce medication requirements quickly, and unadjusted doses of insulin or a sulfonylurea alongside falling glucose can cause hypoglycaemia.

GLP-1 is a gut hormone released after eating. It stimulates insulin release in a glucose-dependent way, meaning it acts when blood glucose is raised and not when it is normal, while also suppressing glucagon and slowing gastric emptying.

That is why this class was developed for type 2 diabetes first, and why weight reduction appeared as a consistent secondary effect. The same molecule at a higher dose became a weight-management treatment: semaglutide is Ozempic for diabetes and Wegovy for weight management.

For someone with both conditions, a treatment acting on both is clinically attractive. Which product and which dose is appropriate depends on the licensed indication and on the clinical picture, and is a prescriber's decision.